Ann: Dimerix presentation at Bioshares Biotech Summit, page-57

yes I agree with you trials rarely run to timelines or budget. what I'm interested in is how they are doing against their peers as a benchmark.
Travere DUPLEX randomised 371 in under 3 years (it's all in their published paper), recruiting the same FSGS population.
DXB phase 3 has been going for over 2 years and just ticked past 100 randomised. It's more likely than not that they will have to run the trial to full completion for GFR slope, 144 isn't likely to cut it statistically just based on what I have read and heard.
So that's a staggering difference in performance don't you think? You say you work for a big 4 Pharma, if you were sitting in your boardroom looking at numbers like this, you'd say you're significantly underperforming vs the competition if they're operating at 2.5 x your pace.